S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

IVVD Invivyd Inc

0.9595

0.0202 (2.15%)

Pre Market

Last Updated: 05:51:14

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more Invivyd Charts.

Invivyd (NASDAQ:IVVD)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more Invivyd Charts.

Invivyd Inc News

Form 8-K - Current report
Monday 24 February 2025 (1 week ago) • Edgar (US Regulatory)

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existi
Monday 24 February 2025 (1 week ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Wednesday 12 February 2025 (3 weeks ago) • Edgar (US Regulatory)

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025
Monday 10 February 2025 (3 weeks ago) • GlobeNewswire Inc.

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold
Wednesday 5 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 3 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
Monday 3 February 2025 (4 weeks ago) • GlobeNewswire Inc.

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
Monday 3 February 2025 (4 weeks ago) • GlobeNewswire Inc.

More Invivyd Inc News Articles

BNP Paribas Issuance

Bmo Us Dollar Money Mark...

DB X-Trackers Nikkei 225...

Us Critical Metals

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions